Work

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy

Year: 2026

Type: article

Abstract: A prime resistance mechanism of glioblastoma to temozolomide is a vulnerability to radiation therapy.

Source: Journal of Clinical Investigation

DOI: 10.1172/jci205299

Authors: Vlad Moisoiu, Roxanne Lourman, Frank Szulzewsky, Tobias Kessler, Giulio Collotta, Antonio Porro, Anne Bertolini, Franziska Singer, Patrick J. Cimino, Caroline Hertler, Wolfgang Wick, Guido Reifenberger, Eric C. Holland, Alessandro A. Sartori, Michael Weller, Hans-Georg Wirsching

Institutions: University of Zurich, University Hospital Zurich, Huntsman Cancer Institute, German Cancer Research Center, Deutsches Konsortium für Translationale Krebsforschung, SIB Swiss Institute of Bioinformatics, ETH Zurich, NEXUS Personalized Health Technologies, Children's National, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, Fred Hutch Cancer Center, Kantonsspital Winterthur

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,200

Funder: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

OpenAlex ID: W7204157801

FWCI:

Cites:

Cited by:

Related to: